GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » EPS without NRI

Tyme Technologies (Tyme Technologies) EPS without NRI : $-0.14 (TTM As of Jun. 2022)


View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies EPS without NRI?

Tyme Technologies's earnings per share without non-recurring items for the three months ended in Jun. 2022 was $-0.04. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.14.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Tyme Technologies's EPS without NRI or its related term are showing as below:

TYME' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -494.4   Med: -28.7   Max: 24.1
Current: 24.1

TYME's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.3 vs TYME: 24.10

Tyme Technologies's EPS (Diluted) for the three months ended in Jun. 2022 was $-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.14.

Tyme Technologies's EPS (Basic) for the three months ended in Jun. 2022 was $-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.14.


Tyme Technologies EPS without NRI Historical Data

The historical data trend for Tyme Technologies's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyme Technologies EPS without NRI Chart

Tyme Technologies Annual Data
Trend Nov12 Nov13 Nov14 Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 -0.32 -0.19 -0.22 -0.14

Tyme Technologies Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 -0.03 -0.04 -0.04

Competitive Comparison of Tyme Technologies's EPS without NRI

For the Biotechnology subindustry, Tyme Technologies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tyme Technologies's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyme Technologies's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Tyme Technologies's PE Ratio without NRI falls into.



Tyme Technologies EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tyme Technologies  (NAS:TYME) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Tyme Technologies EPS without NRI Related Terms

Thank you for viewing the detailed overview of Tyme Technologies's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Tyme Technologies (Tyme Technologies) Business Description

Traded in Other Exchanges
N/A
Address
1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921
Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.
Executives
Michael Demurjian director, 10 percent owner, officer: Chief Operating Officer 157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman director, 10 percent owner, officer: CEO and Chief Science Officer 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl director 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido officer: Chief Financial Officer C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini officer: Corporate Controller 17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry director 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M officer: Acting Chief Medical Officer 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels director 220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman officer: EVP, Product Development 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor officer: President and CFO 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin officer: Chief Operating Officer 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

Tyme Technologies (Tyme Technologies) Headlines

From GuruFocus